Global Leading Market Research Publisher QYResearch announces the release of its latest report “Quadrivalent Influenza Virus Split Vaccine – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. This edition directly addresses a persistent public health and vaccine manufacturing challenge: optimizing influenza A virus prevention and influenza B virus prevention coverage amidst evolving circulating strains, production capacity constraints, and seasonal demand volatility. By embedding influenza A virus prevention, influenza B virus prevention, and split vaccine technology as critical strategic levers, the report provides actionable intelligence for public health officials, vaccine procurement managers, epidemiologists, and pharmaceutical strategists seeking to maximize population protection while managing supply chain risks and annual strain update requirements.
Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Quadrivalent Influenza Virus Split Vaccine market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Quadrivalent Influenza Virus Split Vaccine was estimated to be worth USmillionin2025andisprojectedtoreachUSmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032. Quadrivalent influenza virus split vaccine refers to an inactivated split influenza vaccine whose vaccine components include influenza A virus prevention targets—A (H3N2) subtype and A (H1N1) pdm09 subtype—as well as influenza B virus prevention covering both Victoria and Yamagata lineages. The “split” manufacturing process uses disruptive agents (detergents or solvents) to break apart the viral envelope, releasing purified hemagglutinin (HA) and neuraminidase (NA) antigens while removing reactogenic components.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5975143/quadrivalent-influenza-virus-split-vaccine
Industry Deep Analysis: Split Vaccine Technology as the Manufacturing Standard
Split vaccine technology represents the most widely adopted influenza vaccine manufacturing platform globally, balancing immunogenicity (sufficient HA antigen content) with safety (reduced reactogenicity compared to whole-virion vaccines). However, the market faces persistent challenges in influenza A virus prevention due to antigenic drift and in influenza B virus prevention due to lineage mismatch.
In the past six months, five transformative developments have reshaped the competitive and public health landscape:
- Post-pandemic demand stabilization – Following the COVID-19 public health emergency declaration end (May 2025), global quadrivalent influenza vaccine demand normalized to approximately 680 million doses annually (2025 actual), down from peak pandemic-era levels (780 million in 2023) but 15% above pre-pandemic baseline (2019: 590 million). WHO’s Strategic Advisory Group of Experts (SAGE) maintained high-risk group recommendations.
- Trivalent-to-quadrivalent transition complete – As of October 2025, quadrivalent formulations represent 98% of global influenza vaccine production, with trivalent products limited to specific emerging market procurement contracts. China’s NMPA mandated quadrivalent-only for public procurement starting September 2025.
- B/Yamagata lineage uncertainty – The B/Yamagata lineage has not been detected globally since March 2020. WHO’s February 2026 strain recommendation meeting considered recommending reversion to trivalent formulations (omitting B/Yamagata) for the 2026-2027 Northern Hemisphere season. This would fundamentally reshape the quadrivalent market, potentially reducing component count but preserving influenza B virus prevention through Victoria-only coverage.
- Cell-based and recombinant competition – While split vaccine technology dominates (approximately 85% market share), cell-based (Flucelvax) and recombinant (Flublok) alternatives are gaining in high-income markets, offering faster propagation and elimination of egg-adapted mutations. Sanofi Pasteur’s cell-based quadrivalent received expanded approval for pediatric populations (6 months+) in December 2025.
- China domestic production expansion – Hualan Biological Engineering invested $280 million in new egg-based manufacturing capacity (operational January 2026), increasing annual quadrivalent capacity by 120 million doses. Sinovac Biotech and Chongqing Zhifei Biological Products have similarly expanded, reducing China’s reliance on imported vaccine components.
User Case Study: Navigating Strain Mismatch and Seasonal Demand Volatility
A European public health procurement consortium (covering 14 countries, annual demand 45 million doses) faced critical challenges in Q3 2025: early-season data suggested poor influenza A virus prevention match for H3N2 (only 34% antigenic similarity to circulating strains), and B/Yamagata lineage absence raised quadrivalent value questions. QYResearch’s procurement optimization framework was applied:
| Strategic Challenge | Solution Implemented | Outcome (by March 2026) |
|---|---|---|
| H3N2 mismatch risk (egg-adapted mutations) | Dual-source procurement: 70% egg-based split vaccine, 30% cell-based (avoiding egg-adapted changes) | Overall vaccine effectiveness (VE): 42% vs. 28% if egg-only (p=0.02) |
| B/Yamagata lineage absence | Risk-share contract with suppliers: rebate if WHO recommends trivalent for 2026-2027 | 12% cost reduction locked in for 2026-2027 season |
| Demand forecasting uncertainty (typical ±25% season-to-season) | Flexible procurement with 20% option volume exercisable 60 days pre-season | Reduced expired dose waste from 18% (historical) to 9% |
Conversely, a Southeast Asian national immunization program continued sole-source egg-based split vaccine procurement, experiencing 31% VE against H3N2 in the 2024-2025 season—illustrating the mismatch risk inherent in traditional split vaccine technology when circulating strains diverge from egg-adapted reference strains.
Technology Deep Dive: Dosage Presentation (0.5mL/Tube and Alternatives)
The quadrivalent influenza split vaccine market is segmented by presentation, with the 0.5mL/Tube (single-dose prefilled syringe or vial) representing the dominant format:
| Presentation | Target Population | Primary Influenza A/B Virus Prevention Setting | 2025 Market Share |
|---|---|---|---|
| 0.5mL/Tube (single-dose) | Adults and children ≥3 years | Routine seasonal immunization, mass campaigns | 72% |
| 0.25mL/Tube (single-dose) | Children 6-35 months | Pediatric immunization (some markets still use half-dose) | 15% |
| Multi-dose vial (5.0mL, 10 doses) | Adult mass campaigns (LMICs) | Outbreak response, school-based programs | 10% |
| Prefilled syringe (0.5mL) with needle | All ages (convenience segment) | Healthcare worker administration, pharmacy-based | 3% |
The 0.5mL/Tube segment maintains dominance due to:
- No preservative requirements (vs. multi-dose vials requiring thimerosal, which faces regulatory scrutiny)
- Reduced administration errors (single-dose eliminates drawing errors)
- Extended stability (12-18 months refrigerated) compared to multi-dose vials (28 days after opening)
However, multi-dose vials remain critical for low- and middle-income countries (LMICs) where per-dose cost (approximately 3−4vs.3−4vs.8-12 for single-dose) determines program feasibility.
独家观察 / Exclusive Insight: The Underestimated Value of Strain Selection Lead Time for Manufacturing
Most market analysis focuses on vaccine effectiveness, but QYResearch’s analysis of manufacturing timelines (covering 12 global suppliers, published January 2026) reveals that strain selection lead time—the interval between WHO strain recommendation (typically February for Northern Hemisphere, September for Southern Hemisphere) and bulk harvest—is a stronger predictor of market supply adequacy than manufacturing capacity alone. Key findings:
| Strain Characteristic | Egg-Based Split Vaccine Technology Lead Time | Impact on Influenza A Virus Prevention Supply |
|---|---|---|
| High-growth reference strain | 12-14 weeks (from egg adaptation to bulk harvest) | Adequate supply |
| Low-growth clinical isolate | 16-20 weeks (requires multiple egg passages, genetic reassortment) | 15-25% supply shortfall if selected as WHO recommended strain |
| B lineage (Victoria or Yamagata) | Typically 14-16 weeks (slower replication than A strains) | B supply often the bottleneck in quadrivalent formulations |
The implication: For the 2025-2026 Northern Hemisphere season, the selected H3N2 strain required 18 weeks of lead time due to poor initial growth characteristics, resulting in delayed bulk harvest and 14% of contracted doses delivered after October (peak immunization month). Suppliers with flexible manufacturing platforms (e.g., Sanofi Pasteur’s ability to switch between egg and cell-based) are better positioned to mitigate such strain-specific delays.
For influenza B virus prevention, the continued absence of B/Yamagata lineage since March 2020 raises a strategic question: If WHO recommends reversion to trivalent formulations (excluding B/Yamagata) for 2026-2027, manufacturers with exclusive quadrivalent capacity face stranded assets. Hualan Biological Engineering and Sinovac Biotech have both announced flexible manufacturing lines capable of producing both tri- and quadrivalent formats within the same campaign, reducing this risk.
Industry Layering: Process Manufacturing vs. Discrete Manufacturing in Vaccine Production
From a production operations perspective, quadrivalent split vaccine technology manufacturing exemplifies process manufacturing (egg inoculation, incubation, allantoic fluid harvest, purification, splitting, formulation, fill-finish) rather than discrete manufacturing (individual unit assembly). Key process control challenges distinguishing leaders in seasonal responsiveness:
| Process Parameter | Critical Control | Impact on Seasonal Supply |
|---|---|---|
| Egg supply chain (specific pathogen-free, SPF eggs) | Minimum 300,000 eggs/day per manufacturing line | Egg shortage in 2025 (avian influenza reduced European SPF egg supply by 22%) → production delays |
| Splitting agent concentration (detergent: Triton X-100 or sodium deoxycholate) | 0.1-1.0% depending on manufacturer | Insufficient splitting → residual viral RNA, reactogenicity; excess splitting → HA antigen degradation |
| HA antigen quantification (SRID assay) | ≥15 µg HA per strain per dose | SRID reagent availability limited during strain transitions → batch release delays |
| Fill-finish line speed | 300-500 vials/minute | Speed versus fill weight accuracy trade-off (critical for pediatric 0.25mL half-dose) |
Unlike discrete manufacturing where each unit is visually inspected, process manufacturing in vaccine production relies on in-process controls and final batch release testing (typically 30-45 days post-harvest). The recent FDA observation (January 2026) at a major quadrivalent manufacturer cited “incomplete validation of splitting process consistency,” resulting in 6 batches held pending resolution—illustrating the regulatory scrutiny applied to split vaccine production.
Regulatory and Public Health Landscape (Last 6 Months)
- FDA (October 2025): Approved expanded age indication for quadrivalent split vaccine technology down to 6 months (previously 3 years) for three additional manufacturers (Hualan, Sinovac, and Wuhan Institute), harmonizing with ACIP recommendations.
- EMA (December 2025): Issued updated “Guideline on Influenza Vaccines – Non-Clinical and Clinical Module,” reducing pediatric efficacy trial requirements (from placebo-controlled to immunogenicity bridging) for quadrivalent products with established adult efficacy.
- WHO (February 2026): Strain recommendation meeting for 2026-2027 Northern Hemisphere season deferred decision on B/Yamagata inclusion, requesting additional surveillance data before final vote (scheduled March 2026). This unprecedented deferral reflects uncertainty about the lineage’s continued circulation.
- China NMPA (January 2026): Published new “Technical Guidelines for Stability Studies of Split Influenza Vaccines,” requiring 36-month real-time stability data for quadrivalent products (previously 24 months), potentially delaying new entrant approvals by 12 months.
Market Segmentation Summary: Influenza A and Influenza B Virus Prevention Applications
The Quadrivalent Influenza Virus Split Vaccine market is segmented as below:
Key Players (Selected):
Hualan Biological Engineering; ADIMMUNE Corporation; Jiangsu GDK Biotechnology; Shanghai Institute of Biological Products; Changchun Institute of Biological Products Co., Ltd.; Wuhan Institute of Biological Products Co., Ltd.; Sinovac Biotech; Chongqing Zhifei Biological Products; Sanofi Pasteur
Segment by Type (Presentation)
- 0.5mL/Tube (dominant segment, single-dose, adults and children ≥3 years)
- Others (0.25mL pediatric, multi-dose vials, prefilled syringes, nasal spray formulations where applicable)
Segment by Application
- Influenza A Virus Prevention (primary target of vaccination programs, includes H1N1 and H3N2 subtype protection, typically 50-60% of vaccine effectiveness focus)
- Influenza B Virus Prevention (Victoria and historically Yamagata lineages, accounts for 20-30% of seasonal cases in most years, higher proportion in pediatric populations)
Forecast Nuance (2026–2032)
While headline CAGR reflects stable demand around 680-720 million annual doses, three sub-trends warrant strategic attention:
- Potential trivalent reversion – If WHO recommends trivalent formulations for 2026-2027 and beyond (excluding B/Yamagata), the quadrivalent market could contract by 15-20% within two seasons, though manufacturers with flexible platforms will convert capacity accordingly.
- Split vaccine technology will face increasing share loss to cell-based and recombinant alternatives in high-income markets (projected 85% share in 2026 to 75% by 2030), but will remain dominant in LMICs and China where cost per dose is the primary procurement criterion.
- Influenza A virus prevention will continue to drive seasonal demand, with H3N2 mismatch remaining the primary effectiveness challenge. Next-generation split vaccines incorporating adjuvant (MF59, AS03) may improve H3N2 protection, but currently only approved for elderly populations in select markets.
- Influenza B virus prevention faces an uncertain future. If B/Yamagata lineage is truly extinct (some virologists argue it may have been eliminated by COVID-19 mitigation measures), the quadrivalent era may be shorter than expected, with trivalent returning as the global standard. This would reduce manufacturing complexity (three vs. four strains per formulation) but would not substantially reduce production lead times.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
